Multi-epitope vaccine YL66 and application of preparing vaccine for treating tumour

A technology of YL66 and GST-YL66, applied in the field of biochemistry, can solve the problems of weak immunogenicity, existence of immune tolerance, risk of recombinant eukaryotic expression vectors and lack of amplification ability, etc.

Inactive Publication Date: 2012-09-12
ZHENGZHOU UNIV
View PDF2 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patented technology allows for multiple epitopes on each surface of a virus particle (VLP) molecule or other type of antigenic material attached thereto through chemical bonding between specific amino acids found within it's structure. These techniques can be applied alone or combined with others like gene editing tools to create new types of cancer treatments called chimeras.

Problems solved by technology

Technological Problem: Current Multi-Epitous Vaccination Strategy Targeting Multiple Epithelial Cells Thirms Different Pathways for Immunizing against Cancer Treatment; There were limitations such as lack of strong immunosuppressive effects due to poorly understood mechanisms involved in these pathway systems. Additionally, there was concern about potential adverse side effects caused by current methods like live attension injection or autologous tissue culture transfer techniques.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Multi-epitope vaccine YL66 and application of preparing vaccine for treating tumour
  • Multi-epitope vaccine YL66 and application of preparing vaccine for treating tumour
  • Multi-epitope vaccine YL66 and application of preparing vaccine for treating tumour

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0027] According to the method combining theory and practice, the present invention selects HLA-A2-restricted CTL epitopes that can highly express the antigens COX-2 and MAGE-4 in tumors, and selects a strong effective CD8 + The natural epitope and modified peptide epitope of T cell immune response and specific killing of tumor cells, HLA-A2 restricted CTL epitope p321 obtained from COX-2 and its modified epitope peptide p321-1Y9L and obtained from MAGE -4 The modified epitope peptide p286-1Y2L9L of the HLA-A2 restricted CTL epitope p286 was optimized and combined with the epitope, and Tat-PTD, GSG linker, PADRE and RVKR linker were introduced to construct the multi-epitope fusion vaccine YL66 , the amino acid sequence of YL66 is as follows:

[0028] YGRKKRRQRRR—GSG—AKFVAAWTLKAAA—RVKR—ILIGETIKI—RVKR—YLIGETIKL—RVKR—YLLEHVVRL (Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Gly-Ser-Gly-Ala-Lys- Phe-Val-Ala-Ala-Trp-Thr-Leu-Leu-Ala-Ala-Ala-Arg-Val-Lys-Arg-Ile-Leu-Ile-Gly-Glu-Thr-Ile...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a multi-epitope vaccine YL66, the pronucleus expression carrier pGEX-4T-2-YL66 and the eukaryon expression carrier pCDNA3.1-YL66 are built on the basis of the multi-epitope vaccine YL66, and the fusion protein GST-YL66 is obtained through the pronucleus expression of the carrier pGEX-4T-2-YL66. Through the in-vitro and in-vivo ELISPOT experiment and the LDH experiment on the peripheral blood of a healthy supplier HLA-A2 and the transgenosis mouse HLA-A2.1/Kb, a research is performed on immunological competence of the fusion protein GST-YL66 and the DNA vaccine pCDNA3.1-YL66. The research finds that a certain kill rate for the tumour cell EC-9706 by the specificity CTL induced in-vivo mouse and in-vitro human body is indicated according to the tumour-resistant multi-epitome vaccine, meanwhile the induced CTL has a certain specificity of antigen, and can be applied in a further research on the strategy and the application of building tumour multi-epitome vaccine.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Owner ZHENGZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap